CureApp Hypertension Therapeutics App Clinical trial results announced at ESC Congress 2021 and published in the European Heart Journal, a leading cardiovascular journal
CureApp Hypertension Therapeutics App Clinical trial results announced at ESC Congress 2021 and published in the European Heart Journal, a leading cardiovascular journal Japan’s first major leap toward digital therapeutics in the field of hypertension The results of a Japanese Phase III domestic multicenter randomized controlled trial of a digital therapeutic app for hypertension (DTx) jointly developed by CureApp, Inc. (CEO Kohta Satake; hereafter “the Company”) and Jichi Medical University were presented by Professor Kazuomi Kario of Jichi University’s Department of Cardiovascular Medicine at the European Society of Cardiology Congress held at the end of August 2021 (ESC Congress 2021 - The Digital Experience: Late Breaking Trials in Hypertension). The results of this trial were also published in the European Heart Journal, one of the world’s leading journals on cardiovascular disease. Summary of the clinical trial This clinical trial* 1 ran from January 2020 to December 2020 ev